Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : LHP588 is the company's next-generation, brain penetrant small-molecule gingipain inhibitor, being developed for the treatment of P. gingivalis-positive Alzheimer's disease.
Brand Name : LHP588
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Lead Product(s) : LHP588
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LHP588 is a Phase 2b, orally available small molecule, targets a specific, infectious pathogen, Porphyromonas gingivalis, associated with chronic degenerative and inflammatory disorders including dementia, periodontal disease, atherosclerosis, and orodig...
Brand Name : LHP588
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 10, 2023
Lead Product(s) : LHP588
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : COR588
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quince Therapeutics
Deal Size : $150.0 million
Deal Type : Divestment
Details : Under the agreement, Lighthouse gains exclusive rights to develop, manufacture, and commercialize Quince’s legacy protease inhibitor portfolio including, COR588, COR388, COR852, and COR803 globally.
Brand Name : COR588
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 30, 2023
Lead Product(s) : COR588
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quince Therapeutics
Deal Size : $150.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?